Bon Health Review

The ladder that shows its working

Most sellers here publish a from figure and let you find out later what it assumed. Bon Health publishes a grid: monthly, quarterly, six months, annual, and on each row the billing frequency in words, the effective per-month rate in brackets, the total actually charged, and the saving against paying monthly, as both a dollar amount and a percentage.

That last column is what makes it unusual. A reader who is told the annual tier saves nearly half can immediately see the number they would hand over on day one, and decide whether they want to be locked in for that long with a compounded product. Cora Health publishes every tier too; Bon is the one that puts the total and the discount on the same line as the rate.

One line beneath the grid closes the loop honestly: the FAQ on each page restates the cheapest tier and the month-to-month tier in the same sentence. Our rows carry both ends of each ladder for exactly that reason.

But the number you land on is not the month-to-month rate

The top of each product page shows a per-month figure beside a struck-through, higher one, in the visual grammar every shopper reads as a sale. It is not a sale. The lower figure is the quarterly tier and the struck-out one is the month-to-month rate, and the hero says none of that — it prints the two numbers and the words Original price.

The explanation exists, but it is behind the page's own tab strip, under Pricing rather than the Description a reader arrives on. So the term attached to the headline number takes a click to find, on a page that has otherwise gone to real trouble to be clear.

The first-order promotion has the same shape. It is stated as a percentage off, with free nausea medication thrown in, and never as a figure. That means the amount a new customer actually pays in month one is not published anywhere on the page. Our row carries no introductory rate for this seller, because computing one would be printing a price the seller has never printed.

A brand-name price ladder for a product you cannot buy

There is a Mounjaro product page, built like every other product page, with a hero figure, a struck-through figure, and a four-rung ladder running from a monthly charge to a yearly total in five figures. It reads as an offer right up until the button, which does not say Get started. It says Coming Soon, above the line Available soon — see our compounded version in the meantime.

We have not recorded that ladder as a price. A price you cannot pay is not a price, and putting it on a brand-name board would tell readers that Bon Health is a route to Mounjaro, which its own page says it is not yet. Zera Health does something adjacent and worse — four brand pages whose footer says the company does not supply the drugs — and it is worth knowing that this pattern is common enough to expect.

What the page is honest about is the direction it is steering you. The Mounjaro copy states plainly that the brand's price is set by Eli Lilly, that it commonly runs well over a thousand dollars a month without insurance, and that the compounded tirzepatide is the cheaper route through Bon. That is a fair comparison, printed by the seller, on a page selling the more expensive thing.

The sentence that cost another seller here a warning letter

Both compounded product pages describe the drug as having the same active ingredient as the brand: Ozempic and Wegovy on the semaglutide page, Mounjaro and Zepbound on the tirzepatide page. The homepage repeats it.

In September 2025 the FDA sent a warning letter to Lovely Meds, also reviewed here, quoting that exact construction — same active ingredient as Wegovy and Ozempic, same active ingredient as Zepbound and Mounjaro — and saying the claims imply a compounded product is the same as an FDA-approved one when it is not, which misbrands it. We searched FDA's live warning-letter record for Bon Health Corporation on the day this review was written, with a positive and a negative control in the same run, and found no letter to this company. Nothing here says Bon Health has done anything wrong; only that the agency has objected to this wording elsewhere in this comparison, and a reader is better off knowing that than not.

In Bon Health's favour, the disclaimer sits in three separate places on the same pages: beneath the results chart, in the eligibility paragraph, and in the footer, each saying in plain words that compounded drugs are not FDA-approved and that the FDA does not evaluate them for safety, effectiveness or quality. Several sellers here bury that line or omit it. This one repeats it next to the brand it is comparing itself against.

What it will not tell you

No pharmacy is named. The homepage strip says 503A and 503B compounding, which is a regulatory class rather than a company, and both the privacy policy and the Terms say only that medications are dispensed by independently owned and operated U.S.-licensed pharmacies. Ondra Health names six and gives the class of each; Cora Health names two.

No clinician is named either. The Terms describe individual licensed clinicians employed by or contracted with medical groups, and never name a group or a person. So the two questions a reader most often wants answered before paying — who prepares this, and who is prescribing it — both come back as categories.

The state answer is better. The homepage says licensed in all 50 states and repeats it in a second stat line about physicians in every one, and no exclusion appears on any page we read. That is a real answer, and more than most of this roster gives.

The legal entity is Bon Health Corporation, a Delaware corporation, named in the first sentence of both the privacy policy and the Terms. Worth noting for anyone checking: the cookies URL on this site does not serve a cookies page — it redirects to the privacy policy, which is how a careless citation ends up pointing at a document that does not exist.